CLDXCelldex Therapeutics, Inc.

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$163,000-95.3% YoY

Gross Profit

-$21M-12618.4% margin

Operating Income

-$36M-22328.8% margin

Net Income

-$36M-22088.3% margin

EPS (Diluted)

$-0.77

QoQ Revenue Growth

-6.3%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$23M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$403M

Total Liabilities

$38M

Stockholders' Equity

$365M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$163,000	$3M	-95.3%
Gross Profit	-$21M	-$9M	-131.7%
Operating Income	-$36M	-$13M	-170.8%
Net Income	-$36M	-$13M	-169.2%

Revenue Segments

Contracts and grants

$163,000100%

CLDX Q2 2022 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena